Buprenorphine: A new alternative in the treatment of opioid addiction

TELLİOĞLU, Tahir

Buprenorphine: A new alternative in the treatment of opioid addiction

Tahir TELLİOĞLU (MD, Asst. Professor of Psychiatry and Human Behavior Brown University Medical School, USA)

Klinik Psikofarmakoloji Bülteni

2 0

Yıl: 2010 Cilt: 20 Sayı: 3 Sayfa Aralığı: 261 - 266 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Buprenorphine: A new alternative in the treatment of opioid addiction

Öz:

Opioid agonistleri, opioid bağımlılığı tedavisinde detoksifikasyon ve idame tedavileri olarak sıklıkla kullanılır. Uzun etkili bir opioid agonisti olan metadon, yüksek bağımlılık ve kötüye kullanım riski olması, ve ayrıca sadece belli merkezlerde kullanılabilmesi nedeniyle günümüzde oldukça artan opioid bağımlılarının tedavi ihtiyacına cevap verememektedir. Bir parsiyel opioid agonisti olan buprenorfin, metadona göre daha güvenli profili, uzun etkisi ve muayenehane ortamında kullanılabilmesi sayesinde 2000li yılların başından beri hekimler tarafından opioid detoksifikasyon ve idame tedavisinde tercih edilmektedir.

Anahtar Kelime:

Konular: Farmakoloji ve Eczacılık

Opioid bağımlılığı tedavisinde yeni bir alternatif: Buprenorfin

Öz:

Opioid addiction is a complex disease with severe biological, psychological, and social impacts in the life of the individual, his family and the society. Besides heroin, misuse and abuse of prescription opioid pain medications are rising. Current pharmacological maintenance therapy with methadone accompanied by appropriate psychosocial treatments is a highly effective treatment for opioid addiction. However, due to strict regulations, limited availability, and abuse risk of methadone, new and practical approaches are required. Buprenorphine, a high affinity partial μ opioid agonist, allows qualifying physicians to offer treatment in office-based settings for the detoxification or maintenance of individuals with opioid addiction.

Anahtar Kelime:

Konular: Farmakoloji ve Eczacılık

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık

1. McLellan AT, Lewis DC, O’Brien CP, et al.: Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-1695
2. Leshner AI: Comments on “The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments,” by Phillippe Bourgois. Subst Use Misuse 1998;33:2369-2374
3. Haasen C, van den Brink W: Innovations in agonist maintenance treatment of opioid-dependent patients. Curr Opin Psychiatry 2006;19:631-636
4. ONDCP: National drug control strategy. Edited by Office GP. Washington, D.C, Office of National Drug Control Policy, 2000
5. McCabe SE, Cranford JA, West BT: Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav 2008;33:1297-1305
6. Noble M, Tregear SJ, Treadwell JR, et al.: Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35:214-228,
7. SAMHSA: Results from the 2006 National Survey on Drug Use and National Findings, Office of Applied Studies, 2007
8. Johnston LD, O’Malley, P. M.,Bachman, J.G., Schulenberg, J. E. : Monitoring the future national survey results on drug use, 1975- 2007. Secondary school students in NIH Publication No. 08-6418A Vol. 1. Bethesda, MD, National Institute on Drug Abuse, 2008
9. DHHS: National Estimates of Drug-Related Emergency Department Visits. in Drug Abuse Warning Network, :, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2005
10. Mark TL, Woody GE, Juday T, et al.: The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001;61:195-206
11. White AG, Birnbaum HG, Mareva MN, et al.: Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-479
12. Veilleux JC, Colvin PJ, Anderson J, et al.: A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010;30:155-166
13. DATA: Title XXXVWaiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment http://www.buprenorphine.samhsa.gov/fulllaw. html in Public Law No. 106-310, Drug Addiction Treatment Act, 2000
14. Fiellin DA, O’Connor PG: Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002;347:817-823
15. Ling W, Smith D: Buprenorphine: blending practice and research. J Subst Abuse Treat 2002;23:87-92
16. Pickworth WB, Johnson RE, Holicky BA, et al.: Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 1993;53:570-576
17. Mendelson J, Upton RA, Everhart ET, et al.: Bioavailability of sublingual buprenorphine. J Clin Pharmacol 1997;37:31-37
18. Lintzeris N, Bell J, Bammer G, et al.: A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 2002;97:1395-1404
19. Peachey JE, Lei H: Assessment of opioid dependence with naloxone. Br J Addict 1988;83:193-201
20. Schottenfeld RS, Pakes J, O’Connor P, et al.: Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry 2000;47:1072- 1079
21. Johnson RE, Chutuape MA, Strain EC, et al.: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343:1290-1297 Patients in treatment for opioid addiction received an average daily dose of 16 mg of buprenorphine showed reductions in reported days of heroin use during a 12-week trial. (modified from: Schottenfeld et al. Biological Psychiatry 47(12):1072-1079, 2000)(20).
22. Fudala PJ, Bridge TP, Herbert S, et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349:949-958
23. Ohtani M, Kotaki H, Sawada Y, et al.: Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995;272:505-510
24. Chiang CN, Hawks RL: Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70:S39-47
25. Tellioglu T: The use of urine drug testing to monitor patients receiving chronic opioid therapy for persistent pain conditions. Med Health R I 2008;91:279-280 282
26. Suboxone.com: Qualifications for Suboxone prescription (http:// www.suboxone.com/hcp/certification/qualifications.aspx), 2010
27. Evren EC, Tamar, D., Babayağmur, B., Çakmak, D.: Opioid Bağımlılığının Tedavisinde Buprenorfin:Metadonla Karşılaştırma Çalışmaları. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2000;10:205-212

APA	TELLİOĞLU T (2010). Buprenorphine: A new alternative in the treatment of opioid addiction. , 261 - 266.
Chicago	TELLİOĞLU Tahir Buprenorphine: A new alternative in the treatment of opioid addiction. (2010): 261 - 266.
MLA	TELLİOĞLU Tahir Buprenorphine: A new alternative in the treatment of opioid addiction. , 2010, ss.261 - 266.
AMA	TELLİOĞLU T Buprenorphine: A new alternative in the treatment of opioid addiction. . 2010; 261 - 266.
Vancouver	TELLİOĞLU T Buprenorphine: A new alternative in the treatment of opioid addiction. . 2010; 261 - 266.
IEEE	TELLİOĞLU T "Buprenorphine: A new alternative in the treatment of opioid addiction." , ss.261 - 266, 2010.
ISNAD	TELLİOĞLU, Tahir. "Buprenorphine: A new alternative in the treatment of opioid addiction". (2010), 261-266.

APA	TELLİOĞLU T (2010). Buprenorphine: A new alternative in the treatment of opioid addiction. Klinik Psikofarmakoloji Bülteni, 20(3), 261 - 266.
Chicago	TELLİOĞLU Tahir Buprenorphine: A new alternative in the treatment of opioid addiction. Klinik Psikofarmakoloji Bülteni 20, no.3 (2010): 261 - 266.
MLA	TELLİOĞLU Tahir Buprenorphine: A new alternative in the treatment of opioid addiction. Klinik Psikofarmakoloji Bülteni, vol.20, no.3, 2010, ss.261 - 266.
AMA	TELLİOĞLU T Buprenorphine: A new alternative in the treatment of opioid addiction. Klinik Psikofarmakoloji Bülteni. 2010; 20(3): 261 - 266.
Vancouver	TELLİOĞLU T Buprenorphine: A new alternative in the treatment of opioid addiction. Klinik Psikofarmakoloji Bülteni. 2010; 20(3): 261 - 266.
IEEE	TELLİOĞLU T "Buprenorphine: A new alternative in the treatment of opioid addiction." Klinik Psikofarmakoloji Bülteni, 20, ss.261 - 266, 2010.
ISNAD	TELLİOĞLU, Tahir. "Buprenorphine: A new alternative in the treatment of opioid addiction". Klinik Psikofarmakoloji Bülteni 20/3 (2010), 261-266.